Warady Bradley A, Seligman Paul A, Dahl Naomi V
Department of Pediatrics, Section of Pediatric Nephrology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA.
Clin J Am Soc Nephrol. 2007 Nov;2(6):1140-6. doi: 10.2215/CJN.00830207. Epub 2007 Oct 17.
The clinical use of sodium ferric gluconate complex in iron-deficient pediatric patients receiving hemodialysis was recently approved. This study was designed to describe the pharmacokinetic parameters of the medication.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Iron-deficient pediatric (< or = 15 yr) hemodialysis patients were randomly assigned to two doses (1.5 and 3.0 mg/kg) of sodium ferric gluconate complex. Blood samples taken during a 1-h infusion and at multiple intervals during 48 h were analyzed for total iron, transferrin-bound iron, and sodium ferric gluconate complex-bound iron.
Forty-nine patients (mean age 12.3 +/- 2.5 yr) participated in the study. Mean serum iron concentrations rapidly increased in a dosage-dependent manner. A rapid rise in total serum iron was followed by a slower, less prominent rise in transferrin-bound iron. This was qualitatively confirmed by visualization of the transferrin bands from polyacrylamide gel electrophoresis. Single-dose pharmacokinetics of sodium ferric gluconate complex-bound iron was described using noncompartmental analytical methods. Mean values for the 1.5 mg/Kg dose were as follows: t(1/2) 2.0 +/- 0.7 h, Cmax 1287 mcg/dl, Tmax 1.1 +/- 0.23 h, Cl 0.69 +/- 0.50 L/h, Vd 1.6 +/- 0.6 L, AUC(0-infinity). 9499 +/- 4089 mcg x hr/dl.
The infusion of sodium ferric gluconate complex to pediatric patients who receive hemodialysis appears to result in a delayed transfer of iron to transferrin, likely after an initial movement through the reticuloendothelial system. Differences noted between the pediatric and adult pharmacokinetic data may result from the unique aspects of the study populations and the respective study designs.
葡萄糖酸铁钠复合物在接受血液透析的缺铁儿科患者中的临床应用最近获得批准。本研究旨在描述该药物的药代动力学参数。
设计、地点、参与者及测量方法:缺铁的儿科(≤15岁)血液透析患者被随机分配至两个剂量组(1.5和3.0mg/kg)的葡萄糖酸铁钠复合物。在1小时输注期间及48小时内的多个时间间隔采集血样,分析总铁、转铁蛋白结合铁和葡萄糖酸铁钠复合物结合铁。
49名患者(平均年龄12.3±2.5岁)参与了本研究。平均血清铁浓度以剂量依赖方式迅速升高。血清总铁快速上升后,转铁蛋白结合铁上升较慢且不明显。通过聚丙烯酰胺凝胶电泳转铁蛋白条带的可视化从定性上证实了这一点。使用非房室分析方法描述了葡萄糖酸铁钠复合物结合铁的单剂量药代动力学。1.5mg/Kg剂量组的平均值如下:t(1/2) 2.0±0.7小时,Cmax 1287mcg/dl,Tmax 1.1±0.23小时,Cl 0.69±0.50L/小时,Vd 1.6±0.6L,AUC(0-无穷大) 9499±4089mcg·小时/dl。
对接受血液透析的儿科患者输注葡萄糖酸铁钠复合物似乎会导致铁向转铁蛋白的转移延迟,这可能发生在最初通过网状内皮系统之后。儿科和成人药代动力学数据之间的差异可能源于研究人群的独特方面和各自的研究设计。